EC OK for Jyseleca for adults with moderate to severe active RA

28 September 2020

Hot on the heels of Japanese approval earlier the same day, late Friday Gilead Sciences (Nasdaq: GILD) and partner Galapagos (Euronext: GLPG) revealed that the European Commission (EC) has granted marketing authorization for Jyseleca (filgotinib) 200mg and 100mg tablets.

Jyseleca is a once-daily, oral, JAK1 inhibitor for the treatment of adults with moderate to severe active rheumatoid arthritis (RA) who have responded inadequately to, or are intolerant to, one or more disease modifying anti-rheumatic drugs (DMARDs). Jyseleca may be used as monotherapy or in combination with methotrexate (MTX).

Under the collaboration agreement, Belgium-based Galapagos will now receive a milestone payment of $75 million in recognition of the approval of Jyseleca by the Commission, with the news sending up the share price of the firm by 2.9% to 118.30 euros by close of trading Friday and up a further 4.2% to 123.35 euros on Monday morning.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK